Possibilities of using cytoprotectors in complex therapy of chronic coronary heart disease
- 22 April 2024
- journal article
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 17 (4)
Abstract
The chronic form of coronary heart disease (CHD) is one of the most common types of cardiovascular pathology in the Russian Federation. The main causes of myocardial ischemia are a decrease in coronary reserve, as well as a decrease in coronary blood flow due to atherosclerotic stenosis. When cardiac muscle perfusion is impaired, energy deficiency occurs in cardiomyocytes and an ischemic cascade develops, leading to oxidative stress. In conditions of chronic ischemia in ischemic heart disease, therapy should be aimed at maintaining the energy-synthesizing function of mitochondria by activating the least energy- and oxygen-consuming pathways of ATP synthesis, combating oxidative stress and preventing the death of cardiomyocytes. Cytoprotector drugs meet these requirements. One of their most famous representatives is Mexidol — original (biological reference medicine) ethylmethylhydroxypyridine succinate. Anti-ischemic action is achieved by combining of antioxidant, antihypoxic and membrane-stabilizing pharmacological effects. The review presents the experience of using ethylmethylhydroxypyridine succinate in patients with chronic ischemic heart disease from the perspective of studying their effectiveness and safety using clinical, instrumental and laboratory research methods.Keywords
This publication has 25 references indexed in Scilit:
- Reinventing the Penumbra — the Emerging Clockwork of a Multi-modal Mechanistic ParadigmTranslational Stroke Research, 2022
- Promising effects of emoxypine and its succinate derivative in the management of various diseases-with insights on recent patent applicationsCurrent Research in Pharmacology and Drug Discovery, 2022
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)Russian Journal of Cardiology, 2020
- Combined administration of mexidol with known medicinesS.S. Korsakov Journal of Neurology and Psychiatry, 2019
- CLINICAL ASPECTS OF ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE IN ELDERLY PATIENTS WITH CARDIOVASCULAR PATHOLOGYCardiovascular Therapy and Prevention, 2018
- Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA)S.S. Korsakov Journal of Neurology and Psychiatry, 2017
- ANTIARRHYTHMIC ACTION OF CARDIOCYTOPROTECTORS IN TREATMENT OF ISCHEMIC HEART DISEASE WITH VENTRICULAR ARRHYTHMIASRussian Journal of Cardiology, 2016
- Anxiety in general practice2012
- Vascular NADPH oxidases as drug targets for novel antioxidant strategiesDrug Discovery Today, 2006
- Cardiac Metabolism as a Target for the Treatment of Heart FailureCirculation, 2004